Business Context and Reporting Period
Company: Predictive Oncology Inc. (Note: Request metadata listed "Axe Compute Inc.", but the filing text identifies the registrant as Predictive Oncology Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: September 25, 2025 (Earliest event reported)
Reporting Period: Immediate events occurring between September 19 and September 29, 2025.
The Company is executing a strategic pivot to a digital asset treasury strategy focused on the Aethir (ATH) token, while maintaining its existing AI-driven drug development business. This filing details a dual private placement (cash and cryptocurrency), a reverse stock split, and significant changes to the Board of Directors.
Key Financial Metrics and Transaction Details
Private Placement (Cash Offering):
- Securities: Approximately 55.2 million shares of Common Stock and/or up to 11.5 million Pre-Funded Warrants.
- Purchase Price: $0.7751 per share (pre-split basis).
- Consideration: U.S. Dollars.
Private Placement (Cryptocurrency Offering):
- Securities: Up to 223.6 million Pre-Funded Warrants.
- Purchase Price: Equivalent to $0.7751 per share (pre-split basis) minus $0.01 exercise price.
- Consideration: Digital assets, primarily Aethir (ATH) tokens.
Transaction Costs and Fees:
- Placement Agent (H.C. Wainwright): 5% cash fee on gross cash proceeds; 5% of total shares/warrants issued as Placement Agent Warrants (approx. 3.3 million shares).
- Strategic Advisor (DNA Holdings): Warrants to purchase approx. 20.3 million shares (7% of total placement).
- Asset Management Fee (DNA): 1.00% per annum on Account Assets; 25% incentive fee on profits exceeding 7%.
Stock Split: A 1-for-15 reverse stock split was approved by stockholders on September 19, 2025, effective September 30, 2025. All share counts in this filing are pre-split.
Liquidity and Cash Flow: The filing does not provide current cash balances or liquidity metrics. Proceeds from the private placements are intended to purchase ATH tokens, establish a cryptocurrency treasury, and fund working capital.
Material Changes Versus Prior Period
- Business Strategy Shift: The Company is transitioning its predominant business activity to a digital asset treasury strategy focused on ATH tokens, alongside its existing operations.
- Capital Structure: Significant dilution is expected upon closing due to the issuance of approximately 280 million shares/warrants (55.2M cash shares + 11.5M cash warrants + 223.6M crypto warrants).
- Board Composition:
- Resignation: Nancy Chung-Welch, Ph.D., resigned from the Board effective at the Closing Date.
- Appointment: Shawn Matthews (CEO of DNA Holdings) was appointed to the Board, serving as a Class II director.
- Corporate Governance: Bylaws amended to limit the Board size to a maximum of seven directors.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy:
The Company intends to use net cash proceeds to purchase ATH tokens. The strategy includes staking and lending ATH to generate yield. A special committee and a new Chief Investment Officer will oversee the strategy.
Risks and Contingencies:
- Market Volatility: The Company will be subject to unrealized gains or losses based on the fluctuating market price of ATH tokens.
- Regulatory Uncertainty: Risks related to the evolving regulatory environment for digital assets.
- Closing Conditions: The private placements are subject to customary closing conditions and shareholder approval for the exercise of Cryptocurrency Pre-Funded Warrants.
- Side Letter Obligations: DCI Foundation has agreed to deliver an additional 20% of ATH tokens purchased by the Company on the open market and is responsible for releasing "Locked Crypto" from transfer restrictions.
Unusual Items:
The transaction involves a hybrid offering where a significant portion of the capital raise (Cryptocurrency Offering) is paid in digital assets rather than cash, and the Company is entering into a 10-year asset management agreement with a strategic advisor (DNA) who is also an investor.
Investor Verification Checklist
- Closing Confirmation: Verify if the private placements closed on or about October 2, 2025, and the actual amount of cash and ATH tokens received.
- ATH Valuation: Confirm the current market price of Aethir (ATH) tokens and the total value of the treasury established.
- Shareholder Approval: Verify if shareholder approval was obtained for the exercise of the Cryptocurrency Pre-Funded Warrants.
- Registration Rights: Check the status of the Resale Registration Statements filed for the resale of the new securities.
- Reverse Stock Split: Confirm the post-split share count and adjusted share price following the September 30, 2025, effective date.
- Related Party Transactions: Review the terms of the agreements with DNA Holdings and DCI Foundation for potential conflicts of interest or excessive fees.